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Abstract
Background and Objective The cost-effectiveness of
clinical interventions is often assessed using current care as
the comparator, with national guidelines as a proxy. How-
ever, this comparison is inadequate when clinical practice
differs from guidelines, or when clinical practice differs
between hospitals. We examined the degree of variation in
the way patients with a recent transient ischemic attack (TIA)
or minor ischemic stroke are assessed and used the results to
illustrate the importance of investigating possible clinical
practice variation, and the need to perform hospital-level
cost-effectiveness analyses (CEAs) when variation exists.
Methods Semi-structured interviews were conducted with
16 vascular neurologists in hospitals throughout the
Netherlands. Questions were asked about the use of initial
and confirmatory diagnostic imaging tests to assess carotid
stenosis in patients with a recent TIA or minor ischemic
stroke, criteria to perform confirmatory tests, and criteria for
treatment. We also performed hospital-level CEAs to illus-
trate the consequences of the observed diagnostic strategies
in which the diagnostic test costs, sensitivity and specified
were varied according to the local hospital conditions.
Results 56 % (9/16) of the emergency units and 63 % (10/
16) of the outpatient clinics use the initial and confirmatory
diagnostic tests to assess carotid stenosis in accordance with
the national guidelines. Of the hospitals studied, only one uses
the recommended criteria for use of a confirmatory test, 38 %
(6/16) follow the guidelines for treatment. The most cost-
effective diagnostic test strategy differs between hospitals.
Conclusions If important practice variation exists, hos-
pital-level CEAs should be performed. These CEAs should
include an assessment of the feasibility and costs of
switching to a different strategy.
Key Points for Decision Makers
The cost-effectiveness of clinical interventions is
often assessed using current care as the comparator,
with national guidelines as a proxy.
The use of national guidelines as comparator is
inadequate when clinical practice differs from guide-
lines, or when clinical practice differs between hospitals.
Consideration of clinical practice variation and
deviation from the clinical guidelines should be one
of the first steps in any CEA.
If important practice variation or deviation from the
guidelines exists, hospital-level CEAs should be
performed which compare the care that is actually
provided in hospitals.
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1 Introduction
The cost-effectiveness of clinical interventions (e.g., di-
agnostic tests, therapies or medicines) is normally assessed
using current clinical care as a comparator, with national
guidelines as a proxy for current care [1, 2]. However, this
comparison with guidelines is inadequate when clinical
practice differs significantly from guidelines and is par-
ticularly problematic when clinical practice differs between
hospitals.
The National Institute for Health and Care Excellence
(NICE) in the UK provides guidance through the ‘Guide to
the Methods of Technology Appraisal’ in evaluating clin-
ical care strategies in terms of their cost-effectiveness [3].
In addition, the NICE Diagnostic Assessment Programme
Manual specifically provides guidance in the evaluation of
cost-effectiveness of diagnostic tests and technologies [4].
However, both documents pay little attention to clinical
practice variation and its consequences when performing
relevant cost-effectiveness analyses (CEAs). In practice,
most cost-effectiveness studies do not take into account
possible causes and consequences of clinical practice var-
iation [1, 2].
There are many reasons why clinical practice guideli-
nes are not used in daily practice [5]. In some cases,
hospitals may wilfully deviate from the guidelines if those
guidelines are not be viewed by hospitals as valid. Other
hospitals may have no choice but to deviate from
guidelines if they are simply impossible to implement in
their hospital. In other cases, the guidelines might not be
followed due to solvable problems with logistics or fi-
nancing. Ultimately, various local hospital conditions may
cause variation in clinical practice between hospitals,
which may result in varying costs and health effects (i.e.,
quality-adjusted life years [QALYs]) between hospitals
and consequently important differences in estimated cost-
effectiveness.
A few studies have used large databases to investi-
gate practice variation and the impact it has on costs
and effects [1, 2]. However, their approach is different
from ours since we aim to illustrate the importance of
investigating possible clinical practice variation and
deviation from national guidelines, and the need to
perform hospital-level CEAs, which incorporate local
hospital conditions when important clinical practice
variation exists. We specifically focused on diagnostic
imaging tests for the assessment of carotid stenosis and
criteria for treatment of patients with a recent transient
ischemic attack (TIA) or minor ischemic stroke in the
Netherlands.
2 Methods
2.1 National Stroke Guidelines
After diagnostic evaluation and treatment in the acute
phase, patients with a recent TIA or minor ischemic stroke
undergo an assessment of carotid stenosis and subsequent
treatment as part of the secondary prevention (i.e., to pre-
vent a future stroke). For the assessment of carotid stenosis,
Dutch guidelines recommend duplex ultrasonography
(DUS) as the initial diagnostic test and computed tomog-
raphy angiography (CTA) or magnetic resonance angiog-
raphy (MRA) as a confirmatory test [6]. The criterion for
performing a confirmatory test is moderate (50–69 %)
carotid stenosis for men (based on the initial diagnostic
test) or severe (70–99 %) carotid stenosis for women [6].
No distinction is made in the guidelines between the hos-
pital’s emergency unit and outpatient clinic. Furthermore,
the Dutch guidelines recommend surgery (i.e., carotid en-
darterectomy) for patients (men and women) with a severe
(70–99 %) carotid stenosis and a TIA or minor ischemic
stroke in the past 6 months. In addition, a carotid en-
darterectomy is advised for men with moderate (50–69 %)
carotid stenosis and a TIA or minor ischemic stroke in the
past 3 months [6].
2.2 Interviews and Questionnaire
Semi-structured interviews were conducted with 16 vas-
cular neurologists in 6 academic and 10 non-academic
hospitals throughout the Netherlands. Only one hospital
refused to participate (reason: not interested) resulting in a
response rate of 94 %. We included the hospitals that are
participating in the Plaque at Risk (PARISk) cohort study
[7]. In addition, we do not claim generalizability of the
sample of hospitals that we used in our study, despite in-
cluding 18 % (16/89) of all Dutch hospitals. The interviews
were conducted either face-to-face or by telephone, by four
different interviewers from universities and various uni-
versity medical centers. In total, eleven out of sixteen
(69 %) interviews were conducted face-to-face. All inter-
views were conducted between May 2012 and January
2013.
During the interviews, we queried vascular neurologists
about the type and sequence of diagnostic imaging tests for
the assessment of carotid stenosis as used in their hospitals,
and criteria for subsequent treatment. In particular, ques-
tions were asked about the use of initial and confirmatory
diagnostic imaging tests, and criteria for performing con-
firmatory diagnostic tests. For each hospital, we examined
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diagnostic practice in both the emergency unit and outpa-
tient clinic because we expected differences in the use of
diagnostic tests between these units. In addition, we asked
which criteria were used to perform confirmatory diag-
nostic tests, and which criteria were used to decide for
either surgery (i.e., carotid endarterectomy) in combination
with medicines and lifestyle modification, or medicines
only (e.g., platelet aggregation inhibitors) and lifestyle
modification. We also queried the reasons to deviate from
the Dutch guidelines.
A questionnaire, including both open- and multiple-
choice questions, was used during the interviews (see
Electronic Supplementary Material 1 for the question-
naire). The Dutch stroke guidelines served as the basis for
the questionnaire [6]. The questionnaire was designed in
collaboration with a radiologist and vascular neurologist to
guarantee the clinical relevance of the questions. Subse-
quently, the questionnaire was reviewed by two experts
(two vascular neurologists from two different hospitals),
and adjusted where necessary. Additional questions were
included in the questionnaire and several options were
added to the multiple-choice questions on the use of initial
and confirmatory tests.
2.3 Analysis
We calculated the percentage of hospitals using the rec-
ommended test combination (both initial and confirmatory
test), the percentage of hospitals complying with the
guidelines regarding criteria for use of a confirmatory test,
and the percentage of hospitals complying with recom-
mended criteria for treatment. Hospitals were categorized
as compliant with the recommended test combination when
an initial DUS and confirmatory CTA or MRA [e.g., time-
of-flight-MRA (TOF-MRA) or contrast-enhanced-MRA
(CE-MRA)] is used. Hospitals were categorized as non-
compliant to the guidelines if they use extra criteria (be-
sides degree of carotid stenosis and gender) regarding the
use of a confirmatory test or extra criteria for treatment
(besides degree of carotid stenosis, gender, and time since
TIA or minor ischemic stroke onset).
2.4 Case Study of Hospital-Level CEAs
A case study was used to illustrate the value of performing
hospital-level CEAs when important clinical practice var-
iation exists or when clinical practice differs from guide-
lines. A 5-year decision analytic model for men with a
recent TIA or minor ischemic stroke was used, which in-
corporated four diagnostic strategies (see Fig. 1). We as-
sumed that patients who tested positive (i.e., patients with a
high risk of a recurrent stroke) underwent a carotid en-
darterectomy while others received medicines only. Based
on the performance (i.e., sensitivity and specificity) of the
tests, patients were classified into four groups: true positive
(TP), false positive (FP), false negative (FN), and true
negative (TN). Final health outcomes were dependent on
how patients were classified by the tests and the treatment
that followed. The final health outcomes consisted of a
minor, major, fatal (i.e., death), or no ischemic stroke
event. Death from other causes was incorporated in the
model by using the life expectancy from the Dutch
population [8].
First, a base-case CEA was performed in which the unit
costs of diagnostic tests were based on the national unit
costs from the Dutch Healthcare Authority for 2012 [9] and
Fig. 1 Cost-effectiveness model. An indeterminate test for men
means a moderate (50–69 %) carotid stenosis found in men with an
initial DUS and a TIA or minor ischemic stroke in the past 3 months.
DUS duplex ultrasonography, CTA computed tomography
angiography, CE-MRA contrast-enhanced-magnetic resonance an-
giography, TP true positive, FP false positive, FN false negative, TN
true negative
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the average performance of the tests (see Table 1). The
national unit costs represent a national average based on all
Dutch hospitals. Second, two hospital-level CEAs were
performed, which incorporated hospital-specific unit costs
from 2012 and performance of diagnostic tests from two
hospitals (see Table 1). Since the case study in this paper is
an illustration of the association between practice variation
and the cost-effectiveness of different test strategies, we
chose to include two (out of the 16) hospitals that use two
very different test strategies: one hospital that uses the test
strategy recommended in the guidelines (initial DUS and
confirmatory CTA) and one hospital that does not (initial
CTA and no confirmatory test). The actual diagnostic
strategies from each of the two hospitals, the guideline-
based strategy and other strategies found in clinical prac-
tice were compared with each other in the hospital-level
CEAs to investigate the most cost-effective strategy for
each hospital.
The sensitivity and specificity of each test in the hos-
pital-level CEAs were adjusted based on self-reported
clinician expertise in performing certain tests using the
limits of 95 % confidence intervals as reported in the lit-
erature [10, 11]. Since clinicians from hospital 1 reported
having great expertise in performing a CTA and an average
expertise in performing a DUS and CE-MRA, we assumed
that the sensitivity and specificity of a CTA performed in
that hospital would be higher than average (and set their
values at the upper limit of the 95 % confidence interval)
and an average performance of DUS and CE-MRA. In
contrast, clinicians from hospital 2 reported having great
expertise in performing DUS and CE-MRA, but low ex-
pertise in performing CTA. We therefore assumed higher
values of sensitivity and specificity of DUS and CE-MRA
(and used the upper limit of the 95 % confidence intervals
for DUS and CE-MRA) and a lower performance of CTA
than average in hospital 2 (and used the lower limit of the
95 % confidence interval for CTA).
The total costs per patient consisted of the costs of di-
agnosis, treatment (i.e., carotid endarterectomy and
medicines), and stroke-related societal costs (which com-
prise both healthcare and non-healthcare costs). The aver-
age diagnostic test costs per patient were calculated by
combining the frequency of tests used in the assessment
with their unit costs (see Fig. 1). Figure 1 (upper right-
hand corner) shows the 5-year average treatment and
stroke-related societal costs, and total QALYs for each
category of patients (i.e., TP, FP, FN, and TN). The
treatment costs of TP and FP patients included the costs of
a carotid endarterectomy, which were based on a recent
cost analysis [12], and the costs of medicines for each
category of patients were based on expert opinion. The
utility values and cost input parameters used in the model
can be found in the Electronic Supplementary Material 2
along with their sources. The average treatment and stroke-
related healthcare costs, and QALYs per patient were de-
pendent on the sensitivity and specificity of the diagnostic
tests. For example, a higher sensitivity results in a higher
TP rate with more patients correctly identified for carotid
endarterectomy. Likewise, a higher specificity results in a
higher TN rate, which means that the correctly specified
patients were prevented from unnecessary carotid en-
darterectomies resulting in lower costs and higher QALYs.
All costs were calculated in 2012 Euros using a societal
perspective. Differential discounting was applied in ac-
cordance with the Dutch guidelines, with an annual dis-
count rate of 4.0 % for all costs and 1.5 % for health
effects [13].
3 Results
Tables 2 and 3 show the use of initial and confirmatory
imaging tests at the emergency units and outpatient clinics,
respectively. These tables also show the degree of com-
pliance to the guidelines regarding use of initial and con-
firmatory tests and criteria for use of a confirmatory test.
Table 1 Input parameters of the model
Parameter Base
case
Hospital 1 Hospital 2 Source
Performance of tests
DUS
Sensitivity 89 % 89 % 92 % [10]
Specificity 84 % 84 % 89 %
CTA
Sensitivity 91 % 99 % 71 % [10]
Specificity 99 % 100 % 98 %
CE-MRA
Sensitivity 94 % 94 % 97 % [11]
Specificity 93 % 93 % 96 %
Costs
DUS €63 €78 €60 Base case [9];
Hospital 1 and
2: internal unit
costs
CTA €209 €138 €167 Base case [9];
Hospital 1 and
2: internal unit
costs
CE-MRA €244 €244 €161 Base case [9];
Hospital 1 and
2: internal unit
costs
Carotid
endarterectomy
€6836 €6836 €6836 [12]
DUS duplex ultrasonography, CTA computed tomography angiography,
CE-MRA contrast-enhanced-magnetic resonance angiography
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Table 2 Clinical practice variation in use of diagnostic tests in the emergency unit
Number of hospitals (number of
academic hospitals)
Initial test Confirmatory
test(s)
Compliance to guidelines
regarding use of initial
and confirmatory test?
Compliance to guidelines regarding
criteria for use of a confirmatory test?
Dutch guidelines DUS CTA or MRA If carotid stenosis is[70 %
for women or 50–69 % for men
6 (1) DUS CTA Yes No
2 (0) DUS TOF-MRA Yes Yes (one hospital)
No (one hospital)
1 (0) DUS CE-MRA Yes No
1 (1) DUS or CTA DUS or CTAa No No
1 (0) DUS DUS and CTAb No No
3 (3) CTA DUS No No
1 (1) CTA None No No
1 (0) DUS or CTA DUSc No No
DUS duplex ultrasonography, CTA computed tomography angiography, MRA magnetic resonance angiography, CE-MRA contrast-enhanced-
MRA, TOF-MRA time-of-flight-MRA
a If a DUS is used as initial test, a CTA is used as confirmatory test. If a CTA is used as initial test, a DUS is used as confirmatory test
b DUS is used as confirmatory test, even if an initial DUS is performed. CTA is used when the results of the initial DUS and confirmatory DUS
differ
c DUS is used as confirmatory test, even if an initial DUS is performed. CTA is used when patients were included in a particular clinical study
Table 3 Clinical practice variation in use of diagnostic tests in the outpatient clinic
Number of hospitals
(number of academic
hospitals)
Initial test(s) Confirmatory
test(s)
Compliance to guidelines
regarding use of initial and
confirmatory test?
Compliance to guidelines regarding
criteria for use of a confirmatory test?
Dutch guidelines DUS CTA or MRA If carotid stenosis is[70 % for women
or 50–69 % for men
7 (2) DUS CTA Yes No
2 (0) DUS TOF-MRA Yes Yes (one hospital)
No (one hospital)
1 (0) DUS CE-MRA Yes No
1 (1) DUS or CTA DUS or CTAa No No
1 (0) DUS DUS and CTAb No No
1 (0) DUS None No No
1 (1) DUS and CE-MRA
or DUS and CTAc
None No No
1 (1) CTA None No No
1 (1) CE-MRA DUS No No
DUS duplex ultrasonography, CTA computed tomography angiography, MRA magnetic resonance angiography, CE-MRA contrast-enhanced-
MRA, TOF-MRA time-of-flight-MRA
a If a DUS is used as initial test, a CTA is used as confirmatory test. If a CTA is used as initial test, a DUS is used as confirmatory test
b DUS is used as confirmatory test, even if an initial DUS is performed. CTA is used when the results of the initial DUS and confirmatory DUS
differ
c Choice of DUS and CE-MRA or DUS and CTA is based on logistical reasons
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Table 2 shows that 56 % (9/16) of the hospitals’ emer-
gency units use the test combinations in accordance with
the Dutch guidelines; the other seven hospitals use various
other test combinations, with an initial CTA and confir-
matory DUS as the most common combination.
Table 3 shows that 63 % (10/16) of the hospitals’ out-
patient clinics use the test combinations as advised in the
Dutch guidelines; the other six hospitals use various other
test combinations. In addition, Tables 2 and 3 show that
only one hospital uses the criteria for use of a confirmatory
test according to the guidelines. In contrast, the other hos-
pitals use broader criteria regarding the degree of carotid
stenosis and/or other criteria (e.g., age and plaque charac-
teristics). For example, some hospitals use a confirmatory
test for men with a[70 % carotid stenosis or a confirmatory
test for women with a 50–69 % carotid stenosis.
3.1 Criteria for Treatment
We found that 38 % (6/16) of vascular neurologists strictly
use the criteria for treatment as advised in the guidelines
(i.e., degree of carotid stenosis, gender, and time since TIA
or minor ischemic stroke onset) in their decision for either
surgery or medicines only. The other vascular neurologists
use additional criteria in their decision making about sur-
gery. Patient age and life expectancy play a role in 44 %
(7/16) of the hospitals. Other factors that influence decision
making are co-morbidity, risk of surgery, patient prefer-
ences, duration of complaints, severity of the stroke, and
plaque characteristics.
3.2 Reasons to Deviate from Guidelines Regarding
Use of Initial and Confirmatory Test
According to vascular neurologists, clinical practice var-
iation in the choice of initial and confirmatory tests arises
for different reasons, including varying degrees of exper-
tise in performing diagnostic tests, patient case-mix, clin-
ical reasons, financial incentives, logistics, availability of
imaging technology, and preferences of radiologists, vas-
cular surgeons and vascular neurologists. For example, one
hospital uses a CTA as the initial test due to high expertise
in CTA, even though the guidelines recommend CTA-only
as a confirmatory test. Another hospital uses an initial CTA
instead of the DUS recommended in the guidelines because
CTA is more accurate than DUS. In addition, 25 % (4/16)
of hospitals use a more costly confirmatory test (i.e., CTA
or MRA), even though the guidelines indicate that a DUS is
sufficient. Examples of clinical reasons for deviating from
the guidelines were that MRA could not be used with pa-
tients with a pacemaker and that CE-MRA could not be
used for patients with kidney problems or allergy due to the
contrast liquid.
3.3 Case Study of Hospital-Level CEAs
Figure 2 shows the results of the base-case analysis and
two hospital-level CEAs. For each test strategy, this figure
shows the average costs and health effects in QALYs per
patient. It also shows that the most cost-effective strategy
differs between the base-case analysis and the two hospital-
level CEAs. In the base-case analysis, the CTA-only and
CE-MRA-only strategies were the most cost-effective
strategies (see Fig. 2a). When comparing these two
strategies, the CE-MRA-only strategy leads to slightly
more QALYs (0.001) and higher costs (€287) versus the
CTA-only strategy, resulting in an incremental cost-effec-
tiveness ratio (ICER) of €294,785 per QALY gained. The
high ICER means that the CE-MRA-only strategy is not
cost-effective versus the CTA-only strategy; therefore,
CTA-only is the preferred strategy in the base-case ana-
lysis. However, the results changed when hospital-level
values for unit costs and test performance were used. To
start with, the CTA-only strategy was the dominant strat-
egy in the first hospital, since it had the lowest costs and
highest QALYs of all strategies (see Fig. 2b). In contrast,
the CE-MRA-only strategy was the dominant one in the
second hospital (see Fig. 2c).
4 Conclusions and Discussion
CEAs using guidelines as a comparator are inadequate if
the guidelines are not used in clinical practice. The exis-
tence of important clinical practice variation and the re-
sulting cost differences support the need to perform
hospital-level CEAs which incorporate local hospital con-
ditions (e.g., patient case-mix, costs, availability of fa-
cilities, and expertise). A hospital-level CEA could
examine the cost-effectiveness of the hospital’s current
care strategy versus the strategies used in other hospitals as
well as strategies incorporating new tests or treatments.
This will result in multiple hospital-level ICERs that will
help individual hospitals to explore the potential to im-
prove effectiveness and cost-effectiveness by implement-
ing a different strategy. One possible rule to decide if
hospital-level CEAs should be performed is to compare
which tests or treatments are performed, while another
would be to see if the different strategies used in current
care have different short-term costs and effectiveness (i.e.,
when the costs and effectiveness of the different current
care strategies are similar, then it would be irrelevant to use
multiple comparators). One extreme solution would be to
model the long-term impact on costs and effectiveness
before concluding whether the observed practice variation
is actually important. Lastly, hospital-level CEAs may be
of interest to other parties than just individual hospitals.
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For example, health insurers might want to use hospital-
level CEAs to determine how costly and cost-effective the
care currently provided in hospitals is compared to the
most cost-effective strategy available.
The observed variation in the use of diagnostic tests for
patients with a recent TIA or minor ischemic stroke means
that the most cost-effective diagnostic strategy may differ
between hospitals, as illustrated in our case study. In the
first hospital-level CEA, the average 5-year costs per pa-
tient range from €15,862 to €17,145 between strategies.
While this range may seem small, its effect on budget may
be important depending on the annual volume of patients
[14]. For example, if this hospital were to assess 500 pa-
tients per year (i.e., the average number of patients with a
TIA or ischemic stroke per hospital in the Netherlands in
2012 [8, 15]), the total 5-year costs would range from
€7,930,779 to €8,572,496, meaning a difference of
€641,717.
There are several ways in which practice variation may
result in differences in overall costs and health effects [16,
17]. First of all, a cost difference arises from using different
diagnostic tests. The use of different strategies may also
result in short-term differences in health effects simply due
to differences in complication risks or patient discomfort
(e.g., a more invasive test leads to more discomfort for the
patient). Moreover, the long-term differences in costs and
health effects between the diagnostic strategies are caused
by differences in sensitivity and specificity of the diagnostic
tests used. For example, if patients are more often mis-
classified (i.e., FPs or FNs) by one test than by another test,
this may lead to greater long-term costs and less health.
Even if hospitals use the very same diagnostic test, this too
may result in different long-term costs and health effects if
they use the test results differently when making treatment
decisions or when the test’s diagnostic accuracy differs
between hospitals (as was illustrated in our case study).
If hospitals perform their own hospital-level CEAs, they
should consider the feasibility of the different strategies
being considered as well as incorporate the costs of
switching to a different strategy in the analysis. This holds
true for strategies involving new interventions (such as new
diagnostic tests, medicines or therapies) as well as existing
ones. Switching to a different strategy is only worth con-
sidering when local hospital conditions can readily be
modified (e.g., training clinicians and other healthcare
personnel to use a more advanced imaging test) [18, 19].
If clinicians lack the necessary expertise to perform the
most cost-effective strategy, the hospital-level CEA must
include the extra costs of training. In addition, capacity and
logistical problems may arise because of limited avail-
ability of tests. For example, some small hospitals have
DUS available, but not more expensive scanners like CTA
or MRA. These hospitals currently refer patients to larger
hospitals, resulting in higher costs (e.g., repetition of tests
and travel costs) and a delay in decision making. A CEA
for such small hospitals should include the costs of pur-
chasing an imaging test and possible training costs of
personnel. Viewed in that way, the current strategy may be
more cost-effective due to the relatively high implemen-
tation costs.
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Fig. 2 Hospital-level cost-effectiveness results. Guideline-based
strategy = DUS ? CTA (confirmatory), Hospital 1 currently uses
CTA-only strategy, Hospital 2 currently uses DUS ? CTA (confir-
matory) strategy. DUS duplex ultrasonography, CTA computed
tomography angiography, CE-MRA contrast-enhanced-magnetic reso-
nance angiography, QALY quality-adjusted life year, ICER incre-
mental cost-effectiveness ratio
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Hospitals should have a sufficient understanding of
clinician attitudes when designing an implementation
strategy, since attitudes influence behavior and the choice
of strategy used in clinical practice [18]. Innovation man-
agers or other professionals may assist in the implemen-
tation process, for example by showing clinicians
convincing evidence about the improved effectiveness and/
or cost-effectiveness of a new strategy versus the existing
one [19].
The aim of our paper was to present a major method-
ological issue that seems to be underestimated by many.
We have illustrated the importance of investigating possi-
ble practice variation and deviation from the clinical
guidelines, and have demonstrated the value of performing
hospital-level CEAs based on local hospital conditions
(e.g., unit costs) when important practice variation exists.
The general principles of performing hospital-level CEAs
are valid and should be applied when clinical practice
differs between hospitals or when clinical practice differs
significantly from guidelines, irrespective of the disease
area or countries under study. Further research is recom-
mended that applies the presented general principles of
performing hospital-level CEAs to other disease areas,
types of care, and countries. We do not claim generaliz-
ability of the results from our case study based on two
hospitals, to all Dutch hospitals. The aim of the case study
was merely to illustrate the importance of performing
hospital-level CEAs.
One limitation of performing hospital-level CEAs may
be the feasibility. However, the additional data needed to
perform hospital-level CEAs (when practice variation is
found) are the hospital-specific costs of the tests and the
hospital-specific sensitivity and specificity of tests. We
recommend hospital-level CEAs if data for potentially in-
fluential variables (like the hospital-level costs and per-
formance of tests in this study) can be retrieved or
sufficiently estimated. Moreover, there is a good chance
that hospitals unable to retrieve data on potentially influ-
ential parameters are not functioning very efficiently
compared to those that are. The results of a CEA based on a
hospital’s own data can help a hospital to perform more
efficiently; in the example described in this paper, this
would involve comparing various test strategies and se-
lecting the one that is most cost-effective for that particular
hospital. This approach may demonstrate that one strategy
is the most cost-effective in one hospital, while another
strategy is the most cost-effective in another hospital. In
this sense, the ultimate choice of a hospital may differ from
national guidelines for justifiable reasons.
In conclusion, consideration of clinical practice varia-
tion and deviation from the clinical guidelines should be
one of the first steps in any CEA. If important practice
variation or deviation from the guidelines exists, hospital-
level CEAs should be performed which compare the care
that is actually provided in hospitals. Moreover, a hospital-
level CEA should consider the causes of variation, since
they will affect the feasibility and costs of implementing a
new strategy.
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